Cardiovascular disease remains the leading cause of death worldwide. Despite the availability of effective and relatively low-cost medicines to manage major risk factors such as hypertension and elevated LDL cholesterol, treatment with anti-hypertensive and lipid-modifying agents remains suboptimal in several countries, suggesting scope to improve health outcomes through better use of existing treatments. This report explores the potential health and cost implications of increasing the utilisation of these medicines and examines the factors that may contribute to their underuse. Focusing on Hungary, Latvia and Lithuania, three countries with relatively high cardiovascular disease burden and comparatively low treatment coverage rates, the analysis presents: 1) a quantitative modelling exercise estimating the potential health gains and costs of increasing treatment coverage towards levels observed in comparable higher-performing countries; and 2) a qualitative analysis combining international and country-specific literature reviews with stakeholder interviews to identify barriers and enablers to greater medicine utilisation.
Forthcoming
Tackling underuse of cardiovascular medicines to improve health outcomes
Working paper
Will be released on
Share
Facebook
Twitter
LinkedIn
Abstract
In the same series
-
15 October 202667 Pages
-
16 September 202654 Pages
-
Working paper
A review of gatekeeping and cost‑sharing policies across the OECD
29 May 202662 Pages -
Working paper21 May 202638 Pages
-
10 April 202641 Pages
-
Working paper
Balancing resilience and sustainability in challenging times
31 March 202634 Pages
Related publications
-
Policy brief11 August 202613 Pages
-
Policy brief
Insights from the Patient‑Reported Indicator Surveys (PaRIS)
25 March 202611 Pages -
13 December 201978 Pages
-
17 June 2015180 Pages
-
17 June 20158 Pages
-
Working paper28 October 200452 Pages